Table 1.
Patient, tumor, and treatment characteristics
| Variable | VMAT | Brachytherapy | |||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| No. of patients | 25 | 25 | |||
| Median age (years) | 45 | 48 | |||
| Side | |||||
| Left | 15 | 60 | 16 | 64 | |
| Right | 10 | 40 | 9 | 36 | |
| Site of the tumor | |||||
| Upper outer | 14 | 56 | 10 | 40 | |
| Upper inner | 5 | 20 | 11 | 44 | |
| Lower inner | 2 | 8 | 1 | 4 | |
| Lower outer | 4 | 16 | 3 | 12 | |
| T size | |||||
| T1 | 4 | 16 | 0 | 0 | |
| T2 | 12 | 48 | 22 | 88 | |
| T3 | 9 | 36 | 3 | 12 | |
| N status | |||||
| N0 | 14 | 56 | 17 | 68 | |
| N1 | 11 | 44 | 8 | 32 | |
| Stage | |||||
| 1 | 4 | 16 | 0 | 0 | |
| 2 | 17 | 68 | 24 | 96 | |
| 3 | 4 | 16 | 1 | 4 | |
| Receptor status | |||||
| ER positive | 13 | 52 | 14 | 56 | |
| PR positive | 7 | 28 | 8 | 32 | |
| Her 2 neu positive | 10 | 40 | 11 | 44 | |
| Chemotherapy | |||||
| FAC | 12 | 48 | 15 | 60 | |
| FEC + docetaxel | 11 | 44 | 9 | 36 | |
| Docetaxel + carboplatin | 1 | 4 | 0 | 0 | |
| No chemotherapy | 1 | 4 | 1 | 4 | |
VMAT – volumetric-modulated arc therapy, FAC – 5-Fluorouracil, Adriamycin, Cyclophosphamide, FEC – 5-Fluorouracil, Epirubicin, Cyclophosphamide